XYF19 CAR-T cells / Xi'An Yufan Biotech - LARVOL DELTA

DECREASING HPK1 EXPRESSION IN CD19 CAR-T CELLS: A NOVEL STRATEGY TO OVERCOME CHALLENGES OF CELL THERAPY FOR ADULT (R/R) B-ALL (EHA 2022) - P1 | "The cell dosage of XYF19 was significantly lower than Tecartus and Kymriah, participants were infused with XYF19 CAR-T cells: 3 at low dose (2.0×10 5 /kg), 5 at medium dose (5.0×10 5 /kg), and 3 at high dose (1.0×10 6 /kg). All patients received a conditioning regimen of IV fludarabine (30mg/m 2 /d) for 4 days and cyclophosphamide (500mg/m 2 /d) for 2 days...Conclusion Treatment with XYF19 CAR-T cells promises a novel treatment that can alleviate some of the stern challenges of CD19 CAR-T cell therapy for adult patients with r/r B-ALL. In the current study, this treatment showed robust activity against adult (r/r) B-ALL without >Grade 2 toxicity. This efficacy and safety will be demonstrated in further trials with larger sample sizes."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Inflammation • Leukemia • Oncology • Pediatrics • CD19

Decreasing HPK1 expression in CD19 CAR-T cells: A novel strategy to overcome challenges of cell therapy for adult (r/r) B-ALL. (ASCO 2022) - P1 | "The cell dosage of XYF19 was significantly lower than Tecartus and Kymriah, participants were infused with XYF19 CAR-T cells: 3 at low dose (2.0×105/kg), 5 at medium dose (5.0×105/kg), and 3 at high dose (1.0×106/kg). All patients received a conditioning regimen of IV fludarabine (30mg/m2/d) for 4 days and cyclophosphamide (500mg/m2/d) for 2 days... Treatment with XYF19 CAR-T cells promises a novel treatment that can alleviate some of the stern challenges of CD19 CAR-T cell therapy for adult patients with r/r B-ALL. In the current study, this treatment showed robust activity against adult (r/r) B-ALL without > Grade 2 toxicity. This efficacy and safety will be demonstrated in further trials with larger sample sizes."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Inflammation • Leukemia • Oncology • Pediatrics • CD19